Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 22

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 22
---
icer, Arie Gordashnikov, plans to devote time to our business, but does not intend to focus exclusively on us. Mr. Gordashnikov also
serves in the same capacity for other companies. He may divide his time among these entities and us. Because our Chief Financial Officer
manages other businesses, he will not fully dedicate himself to advancing our business, financial condition, or operational results which
could hurt our business, financial condition and results of operations.

We are dependent upon our officers and directors and their loss, or a reduction in the amount of time they can dedicate to our initial business combination, could adversely affect our ability to operate.

Our operations are
dependent upon a relatively small group of individuals and, in particular, our officers and directors. We believe that our success depends
on the continued service of our officers and directors. In addition, our officers and directors are not required to commit any specified
amount of time to our affairs and, accordingly, will have conflicts of interest in allocating their time among various business activities,
including identifying potential business combinations and monitoring the related due diligence. We do not have key-man insurance
on the life of, any of our directors or officers. The unexpected loss of the services of one or more of our directors or officers could
have a detrimental effect on us.

Clinical drug development and trials involve a lengthy and expensive process with an unpredictable outcome, especially human trials. We cannot be certain the results we observed in our pre-clinical testing will be confirmed in clinical trials or the results of any of our clinical trials will support FDA approval.

Clinical testing is
expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical
study process. Positive results achieved in preclinical or early-stage clinical trials may not indicate the same positive results in
later stage trials, or in trials with more patients. If positive results obtained in early-stage clinical trials are not achieved in
later stage trials, pharmaceutical and biotechnology companies suffer significant setbacks. Moreover, preclinical and clinical data are
often susceptible to varying interpretations and analyses. There is a high failure rate for drugs proceeding through clinical studies,
and product candidates in later stages of clinical studies may fail to show the desired safety and efficacy traits despite having progressed
satisfactorily through preclinical studies and initial clinical studies. Not only are commercialization timelines pushed back, but some
companies, particularly smaller biotechnology companies with limited cash reserves, have discontinued business after releasing news